Report of the first Outcome Measures in Myotonic Dystrophy type 1 (OMMYD-1) international workshop. Clearwater, Florida, November 30, 2011.

Neuromuscular Disorders

Volumn 23, Issue 12, 2013, Pages 1056-1068

  Gagnon, Cynthia ^a,b   Meola, Giovanni ^c   Hébert, Luc J ^h,i   Puymirat, Jack ^d   Laberge, Luc ^e,f   Leone, Mario ^g  

^a Centre de Santé et de Services Sociaux de Jonquière   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c UNIVERSITY OF MILAN   (Italy)

^d LAVAL UNIVERSITY   (Canada)

^e Cégep de Jonquière ^*  (Canada)

^f Centre hospitalier universitaire de Chicoutimi   (Canada)

^g UNIVERSITÉ DU QUÉBEC À CHICOUTIMI   (Canada)

^h UNIVERSITÉ LAVAL   (Canada)

ⁱ Directorate of Medical Policy   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BODY EQUILIBRIUM; BRAIN DISEASE; COGNITIVE DEFECT; DYNAMOMETER; HAND GRIP; HUMAN; MEDICAL RESEARCH; MUSCLE FUNCTION; MUSCLE STRENGTH; MYOTONIC DYSTROPHY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PINCH STRENGTH; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; UNITED STATES; WALKING; WORKSHOP;

CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; FLORIDA; HUMANS; INTERNATIONAL COOPERATION; MYOTONIC DYSTROPHY; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE;

EID: 84888425332     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.07.004     Document Type: Article

References (8)

1. Tugwell P., Boers M., Brooks P., Simon L., Strand V., Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007, 8:38.
2. Maurage C.A., Udd B., Ruchoux M.M., et al. Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease. Neurology 2005, 65:1636-1638.
3. Minnerop M., Weber B., Schoene-Bake J.C., et al. The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease. Brain 2011, 134:3530-3546.
4. Wozniak J.R., Mueller B.A., Bell C.J., Muetzel R.L., Lim K.O., Day J.W. Diffusion tensor imaging reveals widespread white matter abnormalities in children and adolescents with myotonic dystrophy type 1. J Neurol 2013, 260:1122-1131.
5. Heatwole C., Bode R., Johson N., et al. Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 2012, 79:348-357.
6. Nitz J.C., Burns Y.R., Jackson R.V. A longitudinal physical profile assessment of skeletal muscle manifestations in myotonic dystrophy. Clin Rehabil 1999, 13:64-73.
7. Gagnon C., Chouinard M.C., Jean S., et al. Health supervision and anticipatory guidance in adult myotonic dystrophy type 1. Neuromuscul Disord 2010, 20:847-851.
8. Merkel P.A., Seo P., Aries P., et al. Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol 2005, 32:2488-2495.